Novo Nordisk stock gains as analysts see up to 50 percent upside

Novo Nordisk stock (ISIN DK0062498333) is trading near USD 43 per American depositary receipt, after closing around this level on September 17, 2026, while several analyst and valuation models point to sizeable upside potential for the Danish diabetes and obesity specialist.

Analysts and valuation models point to upside

According to MarketBeat on September 17, 2026, Novo Nordisk ADRs trade at about USD 43.20 and carry a consensus price target of USD 64.94, representing roughly 50.3 percent upside from that level.

The same overview shows that the average rating score for Novo Nordisk is 2.11, based on 3 buy ratings, 14 hold ratings and 1 sell rating, underscoring a cautiously positive but not euphoric stance among covering analysts.MarketBeat

In parallel, valuation work from GuruFocus dated September 17, 2026 assigns Novo Nordisk a GF Value estimate of USD 104.84 per ADR, far above the quoted market price in the low USD 40s. One variant of this analysis compares a current price of USD 42.99 with the GF Value of USD 104.84 and concludes the shares are about 59.0 percent undervalued on this basis.

A separate note from GuruFocus on September 17, 2026 highlights that Novo Nordisk shares rose 3.5 percent during that session to USD 43.19, and reiterates that the GF Value of USD 104.84 implies around 58.8 percent upside versus that closing price, reinforcing the picture of a stock still trading below intrinsic value estimates despite the recent rally.

Fundamental backdrop and earnings expectations

While the current articles focus mainly on valuation, consensus data compiled by Yahoo Finance for the Novo-B.CO listing on Nasdaq Copenhagen provide a glimpse of the expected fundamental trajectory for 2026. For the current quarter ending in September 2026, analysts on average forecast revenue of DKK 72.93 billion, with estimates spanning from DKK 70.68 billion to DKK 75.52 billion.

For the full year 2026, the same consensus points to revenue of DKK 299.84 billion, with the low estimate at DKK 272.68 billion and the high estimate at DKK 333.77 billion, indicating expectations of a high double-digit billion turnover and a wide but upwardly sloping revenue corridor.Yahoo Finance

On the earnings side, the same analyst table shows an average earnings per share estimate of DKK 21.58 for 2026, compared with a year-ago EPS figure of DKK 23.03, suggesting that at least one group of analysts expects a modest decline in reported EPS this year despite robust revenue growth.Yahoo Finance

The same table includes a growth indicator showing the current year EPS change at minus 6.28 percent, while revenue growth for the same period is put at minus 6.28 percent as well for the NOVO-B.CO symbol, indicating that consensus currently embeds a slight normalization in profitability after exceptionally strong prior-year results.Yahoo Finance

Risk factors and recent sentiment shifts

The valuation gap identified by both sell-side analysts and quantitative models is a key driver of investor interest, but recent German-language commentary also points to risk factors and sentiment shifts around Novo Nordisk. An analysis from Aktiencheck dated September 18, 2026 notes that the stock climbed intraday by 3.6 percent to EUR 37.77 on a European venue, and that this move took the share price about 25 percent above its 52-week low of EUR 30.25.

In a separate piece, Trading-Treff on September 18, 2026 describes Novo Nordisk shares as trading around EUR 37.77 in pre-market dealings, nearly unchanged compared with the prior day, and observes that the stock currently stands about 7 percent below its 50-day moving average of EUR 40.62 and is down roughly 14 percent since the start of 2026.

This combination of a notable drawdown year-to-date and trading below a short-term moving average, despite remaining comfortably above the 52-week low, describes a phase of consolidation for Novo Nordisk stock in which expectations for upcoming events such as a capital markets day and pipeline updates play an important role in shaping investor sentiment.Trading-Treff

Stock level on Nasdaq Copenhagen and ADR reference price

Novo Nordisk's primary listing is the B share on Nasdaq Copenhagen under the symbol NOVO-B, where the stock recently changed hands around DKK 280.00 in intraday trading on September 17, 2026, according to a live overview from Yahoo Finance. As of that time stamp, the price was up about 0.23 percent on the day.

For international investors using the US market, Novo Nordisk's ADRs trade on the New York Stock Exchange under the ticker NVO. Per the same-day data compiled by MarketBeat on September 17, 2026, NVO was quoted at USD 43.20, up USD 1.49 or 3.57 percent on the session, with the platform noting that the shares had been trading at USD 50.88 on January 1, 2026, implying a decline of about 15.1 percent year-to-date at the current level.

This comparison between the early-year price of USD 50.88 and the more recent USD 43.20 level illustrates that, despite strong demand trends for obesity and diabetes treatments globally, Novo Nordisk stock has given back a portion of prior gains in 2026, leaving room for potential recovery if upcoming earnings and strategic updates reassure the market.MarketBeat

Closing level and investor takeaway

On the primary Nasdaq Copenhagen listing, Novo Nordisk B shares most recently traded around DKK 280.00 during the session on September 17, 2026, while the NVO ADR closed near USD 43.20 on the New York Stock Exchange on the same date, placing the stock well above its 52-week low but still below both its January 2026 level and analyst consensus targets.

More news and analyses on Novo Nordisk stock